Stocks · News reference
Mizuho analyst Graig Suvannavejh maintains Immunocore Holdings (NASDAQ:IMCR) with a Neutral and raises the price target from $34 to $35.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Immunocore Hldgs (NASDAQ:IMCR) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time access to
Immunocore announced it has enrolled 540 patients in the phase III TEBE-AM study evaluating Kimmtrak as monotherapy and in combination with Merck's Keytruda versus investigator's choice in previously treated advanced melanoma. The company expects top-line overall survival data as early as end of 2026. Kimmtrak sales grew 16% year-over-year to $222.6 million in the first half of 2026.
Filed: 2026-09-14 AccNo: 0001671927-26-000026 Size: 491 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve